286
Views
0
CrossRef citations to date
0
Altmetric
Articles

Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome

ORCID Icon, , , , , , , ORCID Icon, , , , , , , , , ORCID Icon, ORCID Icon & show all
Pages 2301-2310 | Received 20 Dec 2021, Accepted 09 May 2022, Published online: 11 Jun 2022

References

  • Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. The Lancet. 2018;392(10147):593–606.
  • Nimer SD. Myelodysplastic syndromes. Blood. 2008;111(10):4841–4851.
  • Badar T, Szabo A, Sallman D, et al. Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leuk Lymphoma. 2020;61(6):1418–1427.
  • Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7(2):118–129.
  • Döhner K, Döhner H. Molecular characterization of acute myeloid leukemia. Haematologica. 2008;93(7):976–982.
  • Theilgaard-Mönch K, Boultwood J, Ferrari S, et al. Gene expression profiling in MDS and AML: potential and future avenues. Leukemia. 2011;25(6):909–920.
  • Kuo FC, Steensma DP, Dal Cin P. Conventional cytogenetics for myeloid neoplasms in the era of next-generation-sequencing. Am J Hematol. 2017;92(3):227–229.
  • Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010;11(1):31–46.
  • Schott AF, Perou CM, Hayes DF. Genome medicine in cancer: what’s in a name? Cancer Res. 2015;75(10):1930–1935.
  • Scheinin I, Sie D, Bengtsson H, et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 2014;24(12):2022–2032.
  • Schoumans J, Suela J, Hastings R, et al. Guidelines for genomic array analysis in acquired haematological neoplastic disorders. Genes Chromosomes Cancer. 2016;55(5):480–491.
  • Mermel CH, Schumacher SE, Hill B, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.
  • Liquori A, Ibañez M, Sargas C, et al. Acute promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene. Cancers (Basel. 2020;12(3):624.
  • Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074.
  • Mareschal S, Palau A, Lindberg J, et al. Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML. Blood Adv. 2021;5(4):1003–1016.
  • Sánchez-Beato M, Sánchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101(4):1220–1235.
  • Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68–79.
  • Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci USA. 2009;106(31):12950–12955.
  • Martín I, Villamón E, Abellán R, et al. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. Br J Haematol. 2021;194(4):708–717.
  • de Thé H, Pandolfi PP, Chen Z. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. Cancer Cell. 2017;32(5):552–560.
  • Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in Early-Stage breast cancer. N Engl J Med. 2016;375(8):717–729.
  • Johnston KM, Sheffield BS, Yip S, et al. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact. Curr Oncol. 2020;27(6):e569–e577.
  • Schmidt KT, Chau CH, Price DK, et al. Precision oncology medicine: the clinical relevance of Patient-Specific biomarkers used to optimize cancer treatment. J Clin Pharmacol. 2016;56(12):1484–1499.
  • Kan Z, Zheng H, Liu X, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23(9):1422–1433.
  • Patch A-M, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–494.
  • Duncavage EJ, Schroeder MC, O'Laughlin M, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N Engl J Med. 2021;384(10):924–935.
  • Duncavage EJ, Schroeder MC, O'Laughlin M, Wilson R, MacMillan S, Bohannon A, et al. Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. N Engl J Med 2021;384:924–935.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.